OraSure Technologies (OSUR) Receiving Somewhat Positive News Coverage, Study Finds

News coverage about OraSure Technologies (NASDAQ:OSUR) has trended somewhat positive this week, according to Accern Sentiment. Accern ranks the sentiment of news coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. OraSure Technologies earned a coverage optimism score of 0.21 on Accern’s scale. Accern also gave media headlines about the medical instruments supplier an impact score of 45.6923414332266 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.

These are some of the media headlines that may have effected Accern Sentiment’s analysis:

OraSure Technologies (NASDAQ:OSUR) opened at $18.19 on Monday. OraSure Technologies has a twelve month low of $8.39 and a twelve month high of $23.01. The stock has a market capitalization of $1,100.00, a PE ratio of 34.98, a P/E/G ratio of 3.49 and a beta of 1.28.

OraSure Technologies (NASDAQ:OSUR) last announced its quarterly earnings data on Wednesday, November 1st. The medical instruments supplier reported $0.09 EPS for the quarter, hitting the Zacks’ consensus estimate of $0.09. The firm had revenue of $42.30 million during the quarter, compared to analyst estimates of $40.87 million. OraSure Technologies had a return on equity of 14.12% and a net margin of 20.48%. The company’s revenue was up 31.0% on a year-over-year basis. During the same period last year, the company earned $0.11 earnings per share. equities analysts predict that OraSure Technologies will post 0.42 EPS for the current fiscal year.

A number of research analysts recently issued reports on OSUR shares. Zacks Investment Research raised OraSure Technologies from a “hold” rating to a “buy” rating and set a $24.00 price target for the company in a report on Saturday, September 9th. Jefferies Group reaffirmed a “buy” rating and issued a $20.00 price target on shares of OraSure Technologies in a report on Tuesday, September 12th. Canaccord Genuity reaffirmed a “buy” rating and issued a $22.00 price target on shares of OraSure Technologies in a report on Tuesday, September 19th. Finally, ValuEngine cut OraSure Technologies from a “buy” rating to a “hold” rating in a report on Thursday, November 2nd. Four investment analysts have rated the stock with a hold rating and four have given a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus price target of $18.21.

In other news, Director Mara G. Aspinall acquired 5,000 shares of the stock in a transaction that occurred on Tuesday, November 7th. The stock was purchased at an average cost of $14.23 per share, for a total transaction of $71,150.00. Following the completion of the transaction, the director now directly owns 5,000 shares in the company, valued at $71,150. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CEO Douglas A. Michels sold 22,923 shares of OraSure Technologies stock in a transaction dated Wednesday, October 4th. The stock was sold at an average price of $23.00, for a total value of $527,229.00. The disclosure for this sale can be found here. 6.40% of the stock is owned by company insiders.

COPYRIGHT VIOLATION WARNING: “OraSure Technologies (OSUR) Receiving Somewhat Positive News Coverage, Study Finds” was first posted by Community Financial News and is the property of of Community Financial News. If you are accessing this news story on another website, it was copied illegally and republished in violation of U.S. & international copyright and trademark laws. The legal version of this news story can be read at https://www.com-unik.info/2017/12/18/orasure-technologies-osur-receiving-somewhat-positive-news-coverage-study-finds.html.

About OraSure Technologies

OraSure Technologies, Inc (OraSure) is involved in the development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices using its technologies, as well as other diagnostic products, including immunoassays and other in vitro diagnostic tests that are used on other specimen types.

Insider Buying and Selling by Quarter for OraSure Technologies (NASDAQ:OSUR)

What are top analysts saying about OraSure Technologies? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for OraSure Technologies and related companies.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit